TBC Astellas Pharma Australia Pty Ltd
Product name
TBC
Accepted date
Feb-2024
Active ingredients
enfortumab vedotin
Proposed indication
Indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
Application type
C (new indication)
Publication date
Feb-2024